Zamtocabtagene autoleucel(Zamtocabtagene autoleucel) - 药物靶点：CD19 x CD20_在研适应症：侵袭性 B 细胞非霍奇金淋巴瘤，伯基特淋巴瘤，成熟B细胞肿瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名

Anti-CD20-anti-CD19 CAR T cells、CD20-CD19-targeting CAR T Cells、DALY II USA

+ [2]

靶点

CD19 x CD20

作用方式

抑制剂

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、T淋巴细胞替代物

治疗领域

肿瘤免疫系统疾病感染+ [7]

在研适应症

侵袭性 B 细胞非霍奇金淋巴瘤伯基特淋巴瘤成熟B细胞肿瘤+ [18]

非在研适应症-

原研机构

Miltenyi Biomedicine GmbH

在研机构

National Institute For Health & Care Research

Miltenyi Biomedicine GmbH

Miltenyi Biotec BV & Co. KG

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

8

项与 Zamtocabtagene autoleucel 相关的临床试验

NCT07178431

/ Not yet recruiting临床1/2期

An Open Label Phase I/IIa, Multicenter, Interventional Single-arm Trial of MB-CART 2019.1 in Patients With Refractory Multiple Sclerosis (MS)

The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.

开始日期2025-10-30

申办/合作机构

Miltenyi Biomedicine GmbH

NCT06508931

/ Recruiting临床2期

A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory (r/r) Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease

This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and <18 years, ≥6 kg body weight [BW]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.

开始日期2025-08-04

申办/合作机构

Miltenyi Biomedicine GmbH

NCT06708845

/ Not yet recruiting临床1期

A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects with Severe Refractory Autoimmune Diseases

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

开始日期2025-01-01

申办/合作机构

Miltenyi Biomedicine GmbH

100 项与 Zamtocabtagene autoleucel 相关的临床结果

登录后查看更多信息

100 项与 Zamtocabtagene autoleucel 相关的转化医学

登录后查看更多信息

100 项与 Zamtocabtagene autoleucel 相关的专利（医药）

登录后查看更多信息

1

项与 Zamtocabtagene autoleucel 相关的文献（医药）

2024-10-01·RMD Open

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel

Article

作者: Heteren, Pearl van ; Nagy, György ; Gopcsa, Laszlo ; Balogh, Alexandra ; Zadoyan, Gregor ; Giba-Kiss, Laura ; Takacs, Peter ; Reti, Marienn ; Remenyi, Peter ; Paksi, Melinda ; Miltenyi, Stefan ; Lakatos, Gergely ; Overstijns, Toon ; Holtkamp, Silke ; Szabo, David

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.

100 项与 Zamtocabtagene autoleucel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
Carney复合症	临床2期	德国	Miltenyi Biomedicine GmbH	2025-10-30
原发性进行性多发性硬化	临床2期	德国	Miltenyi Biomedicine GmbH	2025-10-30
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	法国	Miltenyi Biomedicine GmbH	2025-08-04
伯基特淋巴瘤	临床2期	法国	Miltenyi Biomedicine GmbH	2025-08-04
成熟B细胞肿瘤	临床2期	法国	Miltenyi Biomedicine GmbH	2025-08-04
难治性成熟B细胞非霍奇金淋巴瘤	临床2期	法国	Miltenyi Biomedicine GmbH	2025-08-04
弥漫性大B细胞淋巴瘤	临床2期	奥地利	Miltenyi Biomedicine GmbH	2021-08-18
弥漫性大B细胞淋巴瘤	临床2期	比利时	Miltenyi Biomedicine GmbH	2021-08-18
弥漫性大B细胞淋巴瘤	临床2期	捷克	Miltenyi Biomedicine GmbH	2021-08-18
弥漫性大B细胞淋巴瘤	临床2期	德国	Miltenyi Biomedicine GmbH	2021-08-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Zamto-cel	獵遞築廠觸製餘餘鏇淵(糧蓋餘醖範蓋廠願廠餘) = 32 pts (46.4%) experienced cytokine release syndrome (CRS), all grade 1-2 夢糧構衊選選網鏇範艱 (艱膚鏇艱廠獵鏇獵廠簾 ) 更多	-	2024-12-07
NCT04792489 (DALY II USA, Tandem Meetings ASTCT and CIBMTR2023)	临床2期	难治性弥漫性大 B 细胞淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤 CD20 \| CD19+	27	Zamtocabtagene Autoleucel (zamto-cel)	醖繭選廠壓製獵膚簾醖(繭構憲衊蓋製鹽觸築蓋) = 繭鏇衊獵窪鹽鹽積鹽襯構蓋窪鏇膚艱簾鬱積齋 (選壓獵簾糧鹹餘壓壓廠 ) 更多	积极	2023-02-01
NCT03870945 (ASH 12020 \| ASH 22020) 人工标引	临床1期	B细胞淋巴瘤 CD19 Positive \| CD20 Positive	12	MB-CART2019.1	壓膚顧窪鹹鏇醖構廠範(積繭襯壓顧夢製願艱齋) = CRS grade 1 occurred in 3/6 patients on DL1 and DL2 each, and CRS grade 2 in 2 patients on DL2. 繭醖構繭鹹積網夢淵築 (範淵製繭選構範簾簾廠 ) 更多	积极	2020-11-05
NCT03870945 (ASH 12020 \| ASH 22020) 人工标引	临床1期	B细胞淋巴瘤 CD19 Positive \| CD20 Positive	12	MB-CART2019.1		积极	2020-11-05